Edition:
United States

GlaxoSmithKline PLC (GSK)

GSK on New York Consolidated

42.41USD
28 Mar 2017
Change (% chg)

$-0.28 (-0.66%)
Prev Close
$42.69
Open
$42.61
Day's High
$42.67
Day's Low
$42.37
Volume
1,911,795
Avg. Vol
3,565,583
52-wk High
$45.58
52-wk Low
$37.20

GSK

Chart for GSK

About

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company's segments include Pharmaceuticals, Pharmaceuticals... (more)

Overall

Beta: 0.95
Market Cap(Mil.): $102,807.60
Shares Outstanding(Mil.): 2,458.46
Dividend: 0.58
Yield (%): 4.70

Financials

  GSK Industry Sector
P/E (TTM): 91.87 29.25 30.03
EPS (TTM): 0.46 -- --
ROI: 2.93 13.69 13.19
ROE: 29.24 14.58 14.33

BRIEF-GSK announces U.S. regulatory submission seeking expanded indication for Fluarix Quadrivalent for infants 6 months and older

* GSK announces US regulatory submission seeking expanded indication for Fluarix Quadrivalent (Influenza vaccine) for infants 6 months and older Source text for Eikon: Further company coverage:

Mar 15 2017

Glaxo boss pay cut is a false economy

LONDON (Reuters Breakingviews) - GlaxoSmithKline’s chief executive pay cut is a false economy. The pharmaceutical group will pay new boss Emma Walmsley a quarter less than her predecessor, Andrew Witty, on account of her experience. Yet the modest gains seem out of kilter with the potential cost of inexperience.

Mar 15 2017

Glaxo boss pay cut is a false economy

LONDON (Reuters Breakingviews) - GlaxoSmithKline’s chief executive pay cut is a false economy. The pharmaceutical group will pay new boss Emma Walmsley a quarter less than her predecessor, Andrew Witty, on account of her experience. Yet the modest gains seem out of kilter with the potential cost of inexperience.

Mar 15 2017

BRIEF-GSK says asthma drug Nucala (Mepolizumab) meets primary endpoints

* Phase IIIB Musca study successfully met all its primary and secondary endpoints

Mar 06 2017

BRIEF-GlaxoSmithKline says for results positive in asthma study

* Feb. 23 2017 positive results for Relvar Ellipta lung function study in patients with well-controlled asthma positive headline results from a non-inferiority lung function study read more

Mar 02 2017

BRIEF-Aspen completes acquisition of a portfolio of anaesthetics with GlaxoSmithKline

* Aspen Holdings is pleased to announce that this transaction completed Source text for Eikon: Further company coverage:

Mar 01 2017

BRIEF-GSK reports positive results in study for controlled asthma

* Positive results for Relvar Ellipta lung function study in patients with well-controlled asthma

Feb 23 2017

UPDATE 2-China updates key drug list in boost for Big Pharma

* GSK, AZ, Shire welcome update (Adds GSK statement, analyst comment, details)

Feb 23 2017

Gilead challenges GSK with strong HIV drug data

LONDON Gilead Sciences has thrown down a challenge to GlaxoSmithKline with good clinical trial results for an experimental HIV drug that works in the same way as the British group's successful dolutegravir.

Feb 14 2017

Gilead challenges GSK with strong HIV drug data

LONDON, Feb 14 Gilead Sciences has thrown down a challenge to GlaxoSmithKline with good clinical trial results for an experimental HIV drug that works in the same way as the British group's successful dolutegravir.

Feb 14 2017

More From Around the Web

Competitors

Earnings vs. Estimates